The Initial Evidence Base
From the outset we saw a compelling amount of circumstantial evidence - enough to commit all our resources to developing the investigation.
After careful analysis of this evidence, our conclusions were as follows:
There is longstanding circumstantial evidence that moxa has been used to treat TB in East Asia.
There exists far more powerful evidence from the 1930’s when moxa was used successfully to treat TB in the modern era particularly since these treatments were accompanied by published academic research.
There is also convincing more recent evidence that moxa treatment creates an immune response in both animals and humans.
Seen as a whole, this provided (and still provides) an irresistible argument as to why this treatment should be carefully re-examined in the light of the disease’s current mutations - particularly in the developing world - with a view to seeing particularly if it might improve tendencies in recovery, reduce morbidity and mortality, be in any way effective in the treatment of drug-resistant strains, or even help improve prognoses in cases of co-infection with HIV/AIDS.